An scFv is a small fusion protein. It contains the variable regions of the heavy and light chains of an antibody. It is much smaller than a full IgG. This allows it to penetrate tissues deeply and clear from the blood rapidly.
The field of nuclear medicine is undergoing a significant transformation. The focus has shifted toward targeted delivery systems that can carry radioactive payloads directly to specific disease sites. This approach relies heavily on the quality of the targeting vehicle. Phage display technology stands as a premier method for identifying these vehicles. It allows for the precise selection of antibodies and antibody fragments that meet the rigorous demands of radiopharmaceutical development.
Creative Biolabs' service focuses on radio-conjugate binder discovery. We utilize advanced phage display libraries to isolate high-affinity binders. These binders are optimized for use with radioactive isotopes. Our platform also enables broader discovery of next-generation biologic leads through our integrated Phage Display for Next-Generation Biologic Leads Platform. We support your research goals in creating novel tools for imaging and therapy.
A radiopharmaceutical consists of two main parts. The first is the radioactive isotope, which provides the signal for imaging or the energy for therapy. The second is the targeting vector, or binder. This binder directs the isotope to the specific target antigen on a cell surface. The success of radionuclide therapy or imaging depends on this binder. If the binder is too large, it may circulate in the body for too long. This causes unnecessary radiation exposure to healthy tissues. If the binder does not hold the target tightly enough, the image will be blurry, or the therapeutic effect will be weak.
We specialize in binder selection for radionuclide therapy. We understand that a good antibody for a standard drug is not always a good antibody for a radioconjugate. The requirements are different. We look for binders that are stable, specific, and compatible with the chemical process of isotope labeling.
When we perform radiopharmaceutical antibody screening, we prioritize specific traits.
Phage display is a powerful laboratory technique. It connects a specific protein sequence to the genetic code that produces it. We use libraries containing billions of different antibody fragments. This vast diversity allows us to find binders for almost any target. For radioimmunotherapy (RIT) antibody discovery, phage display offers distinct advantages over animal immunization.
Our platform leverages diverse, high-complexity libraries—including human naïve, synthetic, and immune-derived formats—each explicitly curated for stability, expression, and compatibility with downstream radiolabeling chemistries. Beyond vast diversity, we offer unmatched control over the selection environment. We tailor screening conditions to isolate binders that strictly recognize specific epitopes and retain functionality under distinct pH levels or thermal stresses associated with isotope conjugation. This combination of pre-validated resources and rigorous process control enables a streamlined timeline, with lead identification often achieved within weeks. We deliver fully characterized sequences and purified proteins that are ready to integrate directly into your conjugation workflow.
We offer a modular approach to radio-conjugate binder discovery. You can engage us for the entire pipeline or specific steps.
Fig.1 Phage display workflow for radio-conjugate binder discovery.1,3
We discuss your target. We select the best library (e.g., human scFv, naive, or synthetic). We define the goals for binder selection for radionuclide therapy.
We perform multiple rounds of selection. We use high-stringency washing steps. This removes weak binders. We focus on finding the tightest binders. Crucially, we employ counter-selection (negative selection) strategies using normal tissue lysates or plasma components. This filters out non-specific binders early, ensuring high tumor-to-background (T/B) ratios for your final imaging or therapeutic agent.
Once we have a lead candidate, we can reformat it. We can turn an scFv into a minibody/diabody for radio-imaging and engineer cysteine residues into specific spots. This allows for site-specific isotope labeling, which is cleaner and more consistent.
We go beyond standard binding assays. We understand that radiolabeling often involves harsh conditions (e.g., high temperatures, acidic pH) and the attachment of bulky chelators.
One of the most important factors in nuclear medicine is the size of the binder. Full-sized antibodies (IgG) are large. They stay in the blood for days or weeks. This is good for some therapies, but often bad for imaging. High background radiation in the blood makes it hard to see the target. To solve this, we focus on fast-clearance antibody fragments. These are smaller pieces of an antibody that still retain the ability to bind the target. Phage display is the ideal tool for engineering these fragments.
We generate several formats tailored for medical imaging agents.
Fig.2 Pharmacokinetics comparison of antibody fragments for radio-imaging.2,3
An scFv is a small fusion protein. It contains the variable regions of the heavy and light chains of an antibody. It is much smaller than a full IgG. This allows it to penetrate tissues deeply and clear from the blood rapidly.
The Fab fragment includes the antigen-binding region and part of the constant region. It is more stable than an scFv but still clears faster than a full antibody.
We also offer minibody/diabody for radio-imaging.
The following table illustrates why size matters in radioimmunotherapy and imaging.
| Binder Format | Approximate Molecular Weight | Blood Clearance Rate | Tumor Penetration | Best Application |
|---|---|---|---|---|
| Full IgG | ~150 kDa | Slow (Days/Weeks) | Low | Long-term therapy (non-radioactive) |
| Minibody | ~80 kDa | Moderate (Hours) | Moderate | Immuno-PET Imaging |
| Diabody | ~55 kDa | Fast (Hours) | High | Rapid Imaging / Diagnostics |
| scFv | ~25 kDa | Very Fast (Minutes/Hours) | Very High | Fast clearance antibody fragments |
Radioimmunotherapy is a potent form of treatment. It delivers radiation locally. It affects the target cell and neighboring cells (the crossfire effect). This is effective for solid tumors where not every cell expresses the target. Radioimmunotherapy (RIT) antibody discovery focuses on retention. For therapy, we often want the binder to stay at the tumor site for a longer period. This maximizes the radiation dose delivered to the cancer. However, we still need the unbound portion to clear. We assist in finding the right balance. We can identify binders with different "off-rates" (how fast they let go of the target). This allows researchers to model different dosing strategies.
Fig.3 Mechanism of pretargeted radioimmunotherapy (PRIT) strategy.2,3
Transparency is key to our partnership. At the end of the project, we provide:
The development of medical imaging agents and therapeutic conjugates is complex. It requires a solid foundation. That foundation is the binding molecule. Our team provides expert support in radiopharmaceutical antibody screening. We combine biological expertise with advanced phage display technology. We help you navigate the challenges of radio-conjugate binder discovery. Whether you are developing a new tool for theranostics or exploring radioimmunotherapy, we provide the binders you need. We deliver sequences and proteins that are ready for your conjugation and testing workflows. Contact us today to discuss your target. Let us help you advance your research in nuclear medicine.
Q: Can you screen for binders that work with specific isotopes?
Q: What is the difference between an antibody and a radiopharmaceutical binder?
A: A standard antibody relies on the immune system to kill the cell. A radiopharmaceutical binder acts as a delivery truck. Its main job is to carry the radioactive payload to the right address.
Q: Why are fragments preferred over full antibodies?
A: Fragments are preferred for imaging because they clear fast. This gives a clear picture quickly. For radioimmunotherapy, fragments allow for better penetration into solid tumors.
Q: Why should I choose phage display over traditional hybridoma for developing radiopharmaceuticals?
A: Phage display is superior for this application because we can directly select for specific properties like stability under harsh conjugation conditions. Unlike hybridoma, we can easily generate small fragments like scFvs that offer rapid tissue penetration and blood clearance, which are critical for high-contrast imaging and minimizing radiation toxicity to healthy organs. This method gives us precise control over the selection environment to match your final formulation.
Q: We plan to test in mouse models first. Can you ensure the binders recognize both human and mouse antigens?
A: We can incorporate cross-reactivity assessments into the panning strategy. By alternating screening rounds between human and murine orthologs of your target antigen, we enrich for binders that recognize conserved epitopes. This facilitates a smoother transition from in vitro characterization to in vivo efficacy studies in rodent models, reducing the need for surrogate antibodies during your preclinical testing phases.
Reference
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
